(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.7%.
Lexeo Therapeutics's earnings in 2025 is -$104,966,000.On average, 11 Wall Street analysts forecast LXEO's earnings for 2026 to be -$117,210,348, with the lowest LXEO earnings forecast at -$168,805,090, and the highest LXEO earnings forecast at -$85,066,730. On average, 8 Wall Street analysts forecast LXEO's earnings for 2027 to be -$126,187,790, with the lowest LXEO earnings forecast at -$208,145,259, and the highest LXEO earnings forecast at -$83,533,996.
In 2028, LXEO is forecast to generate -$89,708,724 in earnings, with the lowest earnings forecast at -$97,277,509 and the highest earnings forecast at -$80,468,528.